title: Restoring value to stalled Phase II compounds: the case for developing a novel compound for depression using pharmacogenetics.
authors.forename: Carol
authors.initials: C
authors.lastname: Reed
authors.forename: Matthew
authors.initials: M
authors.lastname: Kalnik
authors.forename: Kevin
authors.initials: K
authors.lastname: Rakin
authors.forename: Maria
authors.initials: M
authors.lastname: Athanasiou
authors.forename: Richard
authors.initials: R
authors.lastname: Judson
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy* / Q000235:genetics; D015195:Drug Design; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends
chemical_list: D000928:Antidepressive Agents